Fresenius Medical Care AG & Co. KGaA
General ticker "FMCQF" information:
- Sector: Health Care
- Industry: Medical - Care Facilities
- Capitalization: $14.8B (TTM average)
Fresenius Medical Care AG & Co. KGaA follows the US Stock Market performance with the rate: 15.6%.
Estimated limits based on current volatility of 0.1%: low 46.62$, high 46.73$
Factors to consider:
- Company pays dividends (annually): last record date 2025-05-26, amount 1.62$ (Y3.48%)
- Total employees count: 47521 as of 2005
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [41.90$, 60.02$]
- 2025-12-31 to 2026-12-31 estimated range: [43.78$, 62.88$]
Financial Metrics affecting the FMCQF estimates:
- Negative: with PPE of 22.8 at the end of fiscal year the price was very high
- Positive: -3.60 < Operating profit margin, % of 7.20
- Positive: Operating cash flow per share per price, % of 18.66 > 13.24
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: -8.75 < Industry operating profit margin (median), % of -3.16
- Positive: 41.86 < Shareholder equity ratio, % of 43.43 <= 63.39
- Positive: 1.87 < Return on assets ratio (scaled to [-100,100]) of 2.16
- Negative: Investing cash flow per share per price, % of -0.66 <= -0.66
- Negative: Industry earnings per price (median), % of 0 <= 0
- Negative: 0.79 < Interest expense per share per price, % of 3.18
Short-term FMCQF quotes
Long-term FMCQF plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | €19,398.00MM | €19,453.62MM | €19,335.91MM |
| Operating Expenses | €17,886.24MM | €18,084.18MM | €17,943.51MM |
| Operating Income | €1,511.76MM | €1,369.44MM | €1,392.39MM |
| Non-Operating Income | €-292.48MM | €-336.42MM | €-335.47MM |
| Interest Expense | €360.14MM | €424.64MM | €407.04MM |
| R&D Expense | €228.62MM | €231.97MM | €183.49MM |
| Income(Loss) | €1,219.28MM | €1,033.02MM | €1,056.93MM |
| Taxes | €324.95MM | €300.56MM | €316.06MM |
| Profit(Loss)* | €673.40MM | €499.00MM | €537.91MM |
| Stockholders Equity | €15,449.00MM | €13,620.26MM | €14,576.56MM |
| Inventory | €2,296.21MM | €2,179.18MM | €2,067.92MM |
| Assets | €35,754.00MM | €33,929.81MM | €33,566.58MM |
| Operating Cash Flow | €2,167.00MM | €2,628.80MM | €2,386.14MM |
| Capital expenditure | €1,411.00MM | €684.60MM | €699.36MM |
| Investing Cash Flow | €-734.73MM | €-544.23MM | €-84.94MM |
| Financing Cash Flow | €-1,617.36MM | €-1,858.53MM | €-2,569.30MM |
| Earnings Per Share** | €2.30 | €1.70 | €1.83 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.